Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05083312




Registration number
NCT05083312
Ethics application status
Date submitted
6/10/2021
Date registered
19/10/2021
Date last updated
21/09/2023

Titles & IDs
Public title
Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial
Scientific title
An Adolescent Sub-study Within FLUTE-2: A Randomized, Double-blind, Placebo-Controlled Study of APT-1011 (Fluticasone Propionate Oral Dispersible Tablet Formulation), With an Open-label Extension, in Adolescent Subjects With Eosinophilic Esophagitis
Secondary ID [1] 0 0
SP-1011-003a
Universal Trial Number (UTN)
Trial acronym
FLUTEEN
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Eosinophilic Esophagitis 0 0
Condition category
Condition code
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Inflammatory and Immune System 0 0 0 0
Allergies

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - APT-1011
Treatment: Drugs - Placebo oral tablet

Experimental: APT-1011 - APT-1011 3 mg HS

Placebo Comparator: Placebo - HS


Treatment: Drugs: APT-1011
APT-1011 is an orally disintegrating tablet that includes fluticasone propionate as its active ingredient.

Treatment: Drugs: Placebo oral tablet
Placebo orally disintegrating tablet
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Week 12 histologic responder rates
Timepoint [1] 0 0
Week 12
Primary outcome [2] 0 0
Mean change in number of dysphagia episodes
Timepoint [2] 0 0
Week 0 to Week 12
Secondary outcome [1] 0 0
Mean change in EREFs from Week 0 to Week 12
Timepoint [1] 0 0
Week 0 to Week 12
Secondary outcome [2] 0 0
Percentage of subjects with <1 peak eos/HPF at Week 12
Timepoint [2] 0 0
Week 12
Secondary outcome [3] 0 0
Mean change in PROSE Symptom Burden Score
Timepoint [3] 0 0
Week 0 to Week 12
Secondary outcome [4] 0 0
Mean change in PROSE day-level difficulty swallowing
Timepoint [4] 0 0
Week 0 to Week 12
Secondary outcome [5] 0 0
Histologic Change from Baseline to Week 12
Timepoint [5] 0 0
Week 0 to Week 12
Secondary outcome [6] 0 0
Percentage of subjects with <15 peak eos/HPF
Timepoint [6] 0 0
Week 12
Secondary outcome [7] 0 0
Mean number of dysphagia-free days
Timepoint [7] 0 0
Week 0 to Week 12

Eligibility
Key inclusion criteria
1. Male or female =12 and <18 years of age

2. Each subject and their parents or legal guardian, must read, understand and provide
consent or assent on the ICF for this study and be willing and able to adhere to
study-related treatment regimens, procedures and visit schedule

3. Diagnosis or presumptive diagnosis of EoE that is confirmed during the Screening
period by histology that demonstrates =15 peak eos/HPF. In order to ensure that a
diagnosis can be made, at least 6 biopsies should be taken from both proximal and
distal specimens (at least 3 each). Mid-esophageal biopsies are not required
(optional). HPF will be defined as a standard area of 235 square microns in a
microscope with 40x lens [0.3 mm^2] and 22 mm ocular.

1. Esophagogastroduodenoscopies and biopsies are to be obtained during the Screening
period

2. Biopsies will be read by a central pathologist

3. Esophagogastroduodenoscopies and biopsies performed outside the study will not be
accepted to meet eligibility criteria

4. Optional biopsies may be taken and processed locally for local use, only where
specified in the local ICF. If serious pathology is unexpectedly encountered,
biopsies of such lesions must be processed locally

4. Have a subject-reported history of =6 episodes of dysphagia in the 14 days prior to
baseline

5. Completion of the daily diary on at least 11 out of the 14 days during the 2-week
Baseline Symptom Assessment
Minimum age
12 Years
Maximum age
17 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Have known contraindication, hypersensitivity, or intolerance to corticosteroids

2. Have a contraindication to, or factors that substantially increase the risk of, EGD
procedure or esophageal biopsy or have narrowing of the esophagus that precludes EGD
with a standard 9 mm endoscope at screening

3. Have history of an esophageal stricture requiring dilatation within the 12 weeks prior
to Screening

4. Bone mineral density >2 SD below height-adjusted for age

5. Have any physical, mental, or social condition or history of illness or laboratory
abnormality that in the Investigator's judgment might interfere with study procedures
or the ability of the subject to adhere to and complete the study or increase the
safety risk to the subject such as uncontrolled diabetes or hypertension or may
increase risk of corticosteroid toxicity (e.g., abnormal bone mineral density)

6. History of recurrent (persistent) or current oral or esophageal mucosal infection due
to inhaled or nasal corticosteroids

7. Have any mouth or dental condition that prevents normal eating (excluding braces)

8. Have any condition affecting the esophageal mucosa or altering esophageal motility
other than EoE, including erosive esophagitis (grade B or higher as per the Los
Angeles Classification of Gastroesophageal Reflux Disease, hiatus hernia longer than 3
cm, Barrett's esophagus, and achalasia)

9. Use of systemic (oral or parenteral) corticosteroids within 60 days before Screening,
use of swallowed corticosteroids within 30 days before Screening

10. Initiation of either inhaled or nasal corticosteroids or high-potency dermal topical
corticosteroids within 30 days before Screening

11. Use of calcineurin inhibitors or purine analogues (azathioprine, 6-mercaptopurine) in
the 12 weeks before Screening

12. Use of potent CYP 3A4 inhibitors (e.g., ritonavir and ketoconazole) in the 12 weeks
before Screening

13. Initiation of an elimination diet or elemental diet within 30 days before Screening
(diet must remain stable after signing ICF)

14. Morning (07:00 to 09:00, or as close to that window as possible) serum cortisol level
=5 µg/dL (138 nmol/L) that is not responsive to ACTH stimulation: defined as a serum
cortisol level <16 µg/dL (440 nmol/L) at 60 minutes with ACTH stimulation test using
250 µg cosyntropin (i.e., an abnormal result on the ACTH stimulation test)

15. Use of biologic immunomodulators in the 24 weeks before Screening (environmental
allergen desensitization injection or oral therapy (excluding food allergen
desensitization) is allowed as long as the course of therapy is not altered during the
study period)

16. Subjects who have initiated, discontinued, or changed dosage regimen of histamine H2
receptor antagonists, antacids or antihistamines, leukotriene inhibitors or sodium
cromolyn within 4 weeks before qualifying endoscopy during Screening. If already
receiving these drugs, the dosage must remain constant throughout the study

17. Subjects who have changed dosage regimen of PPIs within 8 weeks before qualifying
endoscopy. If already receiving PPIs, the dosage must remain constant throughout the
study

18. Infection with hepatitis B, hepatitis C, or human immunodeficiency virus

19. Have gastrointestinal bleeding or documented active peptic ulcer within 4 weeks prior
to Screening or entering a new study period

20. Have chronic infection such as prior or active tuberculosis, active chicken pox or
measles or absence of prior measles, mumps and rubella vaccine. Subjects with
tuberculosis exposure or who live in, or travel to, high endemic areas should be
assessed locally for tuberculosis before consideration for the study

21. Immunosuppression or immunodeficiency disorder

22. Current malignancy or malignancy within 3 years of Screening. Subjects in remission
for at least 3 years post-treatment may be enrolled.

23. Known severe bleeding disorder

24. Have a history or presence of Crohn's disease, celiac disease, or other inflammatory
disease of the gastrointestinal tract, including eosinophilic gastroenteritis

25. Have current drug abuse in the opinion of the Investigator.

26. Have current alcohol abuse in the opinion of the Investigator.

27. Female subjects who are pregnant, breastfeeding, or planning to become pregnant during
the study

28. Sexually active females of childbearing potential who do not agree to follow highly
effective contraceptive methods through the End of Study visit

29. Have received an investigational product, as part of a clinical trial within 30 days
(or 5 half-lives, whichever is longest) of Screening. Subjects who are currently
participating in observational studies or enrolled in patient registries are allowed
in this study

30. Have participated in a prior study with investigational product APT-1011

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
5/09/2022
Sample size
Target
Accrual to date
Final
6
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Royal Children's Hospital - Melbourne
Recruitment postcode(s) [1] 0 0
3052 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Indiana
Country [2] 0 0
United States of America
State/province [2] 0 0
Massachusetts

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ellodi Pharmaceuticals, LP
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This is a randomized, double-blind, placebo-controlled study of APT-1011, followed by an
open-label extension (OLE) in adolescents (=12 to <18 years) with EoE.
Trial website
https://clinicaltrials.gov/ct2/show/NCT05083312
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Mirna Chehade, MD, MPH
Address 0 0
Mount Sinai Center for Eosinophilic Disorders
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05083312